(Q36597897)

15 August 2017

title

Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia (English)

1 reference

15 August 2017

0 references

Vincent H Mabasa

1

1 reference

15 August 2017

Suzanne C M Taylor

series ordinal

2

1 reference

15 August 2017

publication date

1 June 2006

1 reference

Journal of Oncology Pharmacy Practice

15 August 2017

published in

1 reference

15 August 2017

volume

12

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

105-111

1 reference

Malignant gliomas in 2005: where to GO from here?

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069161

Temozolomide in the treatment of recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069161

Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069161

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069161

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069161

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069161

Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069161

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069161

Temozolomide as first-line agent in treating high-grade gliomas: phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069161

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069161

21 January 2018

Identifiers

DOI

10.1177/1078155206069161

1 reference

15 August 2017

1 reference